Segment, Geographic and Other Revenue Information - Revenues By Products - Footnotes (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 02, 2023	Apr. 03, 2022
Revenue from External Customer [Line Items]
Revenues		$ 18,282	$ 25,661
Business Innovation Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[1]	310	338
Business Innovation Segment [Member] | Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	306	338
BioNTech [Member] | Business Innovation Segment [Member] | Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues		$ 5	$ 47

[1] See Note 1A in our 2022 Form 10-K for information about our recent organizational changes within Biopharma. See Note 13A above for information about Business Innovation. Prior-period financial information has been revised to reflect the current period presentation.

[2] PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($5 million and $47 million for the first quarters of 2023 and 2022, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships.